We have the solution Oncology

BioMeca démontre l'effet thérapeutique en oncologie BioMeca démontre l'effet thérapeutique en oncologie

BioMeca solutions

BioMeca® has been studied mechanical structure and morphometry of ExtraCellular Matrix (ECM) synthetized by cancer cells. We focused with our partner to investigate specific cancer cells whose express a putative protein tumor suppressors controlling cell death commitment.

BioMeca® is also able to quantify stiffness parameters of pancreatic tumour tissues with AFM (Atomic Force Microscopy). We will carry out experiments on mice pancreatic tumor tissues treated or not with a stromal modulator.

Light on our solutions

Case study

How to mechanically characterize the extracellular matrix synthesized by lung cancer cells ?

A new dependence receptors family (DR) has been discovered by one of our academic partner. These receptors inhibit tumor progression by inducing apoptosis when cancer cells are in absence of DR ligands. Due to the frequent inactivation of their apoptotic function in human cancers, DRs are now considered as tumor suppressors. A selective asset allowing tumor escape would be to loose this apoptotic function, either in losing DR itself or in increasing DR ligand presence.

See study

Case study

How to characterize tissue stiffness in pancreatic cancer to modulate tumour progression ?

Pancreatic ductal adenocarcinoma (PDAC) is the fourth most frequent cause of cancer-related deaths worldwide and should become the second one hence 2030.The extracellular matrix (ECM) in the tumor microenvironment modulates the cancer cell phenotype, especially in pancreatic ductal adenocarcinoma (PDAC), a tumor characterized by an intense desmoplastic reaction.

See study

Tool choice
Need more innovative pharmacological solutions?